

University of Groningen

Cardiac Transthyretin-derived Amyloidosis

Klaassen, Sebastiaan

DOI:
[10.33612/diss.255251963](https://doi.org/10.33612/diss.255251963)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Klaassen, S. (2022). *Cardiac Transthyretin-derived Amyloidosis*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.255251963>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Cardiac Transthyretin- derived Amyloidosis

Sebastiaan H.C. Klaassen

Colofon

The contribution of Alnylam to the costs of printing of the publication of this thesis is gratefully acknowledged.

Provided by thesis specialist Ridderprint, ridderprint.nl

Printing: Ridderprint
Layout and design: Selma Hoitink, persoonlijkproefschrift.nl
Cover design: H.C. Klaassen

Copyright 2022 © Sebastiaan Klaassen
The Netherlands. All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission of the author.



rijksuniversiteit
 groningen

Cardiac Transthyretin-derived Amyloidosis

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
woensdag 7 december 2022 om 12.45 uur

door

Sebastiaan Harm Cornelis Klaassen

geboren op 14 mei 1992
te Utrecht

Promotores

Prof. dr. D.J. van Veldhuisen
Prof. dr. M.P. van den Berg
Prof. dr. P. van der Meer

Copromotor

Dr. H.L.A. Nienhuis

Beoordelingscommissie

Prof. dr. A.A. Voors
Prof. dr. R.A.J.O. Dierckx
Prof. dr. K. Vernooy

Paranimfen

Robin R. Neef, MSc.

Hidde H. Veenis, BBA.

Financial support by the Dutch Heart Foundation for the publication of this thesis is gratefully acknowledged

Content

Chapter 1	Introduction	9
Part 1 : Hereditary Transthyretin-derived amyloidosis		
Chapter 2	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G), <i>Cardiovasc. Pathol., vol. 29, 2017.</i>	23
Chapter 3	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>Am J Cardiol. 2018;121(1)</i>	35
Chapter 4	Cardiac Screening of Amyloid TTR Mutation Carriers: Complementary value of Echocardiographic Global Longitudinal Strain Imaging vs Bonescintigraphy. <i>Submitted</i>	57
Part 2: Wildtype Transthyretin-derived amyloidosis		
Chapter 5	Cardiac Transthyretin-derived amyloidosis: An emerging target in heart failure with Preserved Ejection Fraction? <i>Cardiac Failure Review 2020;6e21</i>	77
Chapter 6	Wild-type transthyretin amyloidosis in the heart failure population with preserved or midrange ejection fraction: its identification using differentially expressed serum proteins. <i>Submitted</i>	89
Chapter 7	Heart Failure with Preserved Ejection Fraction, Atrial Fibrillation, and the Role of Senile Amyloidosis. <i>European Heart Journal 2019; 40(16):1287–93.</i>	111
Chapter 8	Summary, discussion and future perspectives	129
Appendices	I Dutch summary Nederlandse samenvatting	140
	II Acknowledgements Dankwoord	142
	III List of publications	145
	IV About the author	147

